EA202192349A1 - Комбинации, пригодные в способе лечения саркомы - Google Patents
Комбинации, пригодные в способе лечения саркомыInfo
- Publication number
- EA202192349A1 EA202192349A1 EA202192349A EA202192349A EA202192349A1 EA 202192349 A1 EA202192349 A1 EA 202192349A1 EA 202192349 A EA202192349 A EA 202192349A EA 202192349 A EA202192349 A EA 202192349A EA 202192349 A1 EA202192349 A1 EA 202192349A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sarcoma
- subject
- treatment
- combinations suitable
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825017P | 2019-03-27 | 2019-03-27 | |
| PCT/US2020/025532 WO2020198705A1 (en) | 2019-03-27 | 2020-03-27 | Combinations useful in a method for treating sarcoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192349A1 true EA202192349A1 (ru) | 2022-02-01 |
Family
ID=72609016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192349A EA202192349A1 (ru) | 2019-03-27 | 2020-03-27 | Комбинации, пригодные в способе лечения саркомы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220152024A1 (https=) |
| EP (1) | EP3947379A4 (https=) |
| JP (1) | JP7602481B2 (https=) |
| CN (1) | CN114096537B (https=) |
| AU (1) | AU2020248103A1 (https=) |
| BR (1) | BR112021019170A2 (https=) |
| CA (1) | CA3134648A1 (https=) |
| EA (1) | EA202192349A1 (https=) |
| IL (1) | IL286647A (https=) |
| MX (1) | MX2021011688A (https=) |
| WO (1) | WO2020198705A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (https=) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| WO2008075330A1 (en) * | 2006-12-20 | 2008-06-26 | J-C Health Care Ltd. | Method for administration of pegylated liposomal doxorubicin |
| NZ746607A (en) * | 2012-11-21 | 2019-11-29 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| EP3836932A2 (en) * | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
| US20220185795A1 (en) * | 2019-03-11 | 2022-06-16 | Ptc Therapeutics, Inc. | Compound form having enhanced bioavailability and formulations thereof |
-
2020
- 2020-03-27 BR BR112021019170A patent/BR112021019170A2/pt not_active Application Discontinuation
- 2020-03-27 CA CA3134648A patent/CA3134648A1/en active Pending
- 2020-03-27 AU AU2020248103A patent/AU2020248103A1/en not_active Abandoned
- 2020-03-27 EP EP20776386.3A patent/EP3947379A4/en not_active Withdrawn
- 2020-03-27 EA EA202192349A patent/EA202192349A1/ru unknown
- 2020-03-27 MX MX2021011688A patent/MX2021011688A/es unknown
- 2020-03-27 JP JP2021557396A patent/JP7602481B2/ja active Active
- 2020-03-27 CN CN202080039624.8A patent/CN114096537B/zh active Active
- 2020-03-27 US US17/441,355 patent/US20220152024A1/en not_active Abandoned
- 2020-03-27 WO PCT/US2020/025532 patent/WO2020198705A1/en not_active Ceased
-
2021
- 2021-09-23 IL IL286647A patent/IL286647A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022519930A (ja) | 2022-03-25 |
| IL286647A (en) | 2021-10-31 |
| JP7602481B2 (ja) | 2024-12-18 |
| AU2020248103A1 (en) | 2021-10-21 |
| CN114096537A (zh) | 2022-02-25 |
| CN114096537B (zh) | 2025-01-10 |
| EP3947379A4 (en) | 2022-12-21 |
| WO2020198705A1 (en) | 2020-10-01 |
| EP3947379A1 (en) | 2022-02-09 |
| MX2021011688A (es) | 2022-01-24 |
| US20220152024A1 (en) | 2022-05-19 |
| BR112021019170A2 (pt) | 2022-03-03 |
| CA3134648A1 (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125071T1 (el) | Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη | |
| EA202090061A1 (ru) | Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза | |
| MX2024008096A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| GEAP202315703A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
| AR096478A1 (es) | Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos | |
| MX389999B (es) | Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral | |
| EA201591362A1 (ru) | Соединения и способы лечения бактериальных инфекций | |
| EA201792287A1 (ru) | Способы лечения рака | |
| EA201591399A1 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| EA202091881A1 (ru) | Соединения для лечения боли | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| MX389692B (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc. | |
| CL2015002171A1 (es) | Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| CY1125444T1 (el) | Συνθεσεις εναντι μολυνσεων καντιντιασης | |
| MX2019001225A (es) | Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo. | |
| CO2021014747A2 (es) | Métodos para el tratamiento de βeta-talasemia | |
| CL2018001719A1 (es) | Tratamiento contra el mieloma múltiple (divisional solicitud 201600396) | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| EA202192349A1 (ru) | Комбинации, пригодные в способе лечения саркомы | |
| EA202091694A1 (ru) | Ингибиторы pd-1/pd-l1 | |
| EA201990443A1 (ru) | Новое применение n,n-бис-2 -меркаптоэтилизофталамида | |
| EA202192117A1 (ru) | Способ лечения множественной миеломы |